Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to $15.5 million.

  • Outlook Therapeutics' Cash from Financing Activities rose 79151.12% to $15.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.8 million, marking a year-over-year increase of 12611.33%. This contributed to the annual value of $45.0 million for FY2025, which is 2543.44% down from last year.
  • Outlook Therapeutics' Cash from Financing Activities amounted to $15.5 million in Q4 2025, which was up 79151.12% from $11.6 million recorded in Q3 2025.
  • Outlook Therapeutics' 5-year Cash from Financing Activities high stood at $18.4 million for Q1 2025, and its period low was $1.7 million during Q4 2024.